News Releases

April 15, 2021 at 8:35 AM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2021 Financial Results

ATLANTA , April 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2021 financial results will be released on Thursday, April 29, 2021 after the market closes. On that day, the Company
April 7, 2021 at 8:35 AM EDT

Summary Toggle CryoLife to Participate in 20th Annual Needham Virtual Healthcare Conference

ATLANTA , April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20 th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 . The Company's
March 9, 2021 at 8:35 AM EST

Summary Toggle CryoLife to Participate in Oppenheimer 31st Annual Virtual Healthcare Conference

ATLANTA , March 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Oppenheimer 31 st Annual Virtual Healthcare conference on Tuesday, March 16 - 17, 2021. The
February 11, 2021 at 4:05 PM EST

Summary Toggle CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results

ATLANTA , Feb. 11, 2021 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved total revenues of $67.9 million in the fourth quarter 2020 versus $69.7 million in the fourth quarter of 2019 Total revenues decreased 3% on a GAAP basis and 5% on a non-GAAP proforma constant
January 28, 2021 at 8:30 AM EST

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2020 Financial Results

ATLANTA , Jan. 28, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2020 financial results will be released on Thursday, February 11, 2021 after the market closes. On that
November 19, 2020 at 8:30 AM EST

Summary Toggle CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020

Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress ATLANTA , Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will
November 4, 2020 at 4:05 PM EST

Summary Toggle CryoLife Reports Third Quarter 2020 Financial Results

ATLANTA , Nov. 4, 2020 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $65.1 million in the third quarter 2020 versus $67.9 million in the third quarter of 2019 Total revenues decreased 4% on a GAAP and non-GAAP constant currency basis versus third
October 21, 2020 at 8:04 AM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results

ATLANTA , Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes. On that day, the Company
September 8, 2020 at 4:47 PM EDT

Summary Toggle CryoLife to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

ATLANTA , Sept. 8, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference .
September 2, 2020 at 4:02 PM EDT

Summary Toggle CryoLife Acquires Ascyrus Medical

Conference Call and Webcast Today, September 2, 2020 at 5:00 pm ET ATLANTA , Sept. 2, 2020 /PRNewswire/ -- CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has acquired Ascyrus Medical LLC (Ascyrus).